Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bebulin is a 3-factor prothrombin complex concentrate (PCC) derived from human plasma, containing concentrated levels of coagulation factors II, IX, and X, with low levels of factor VII. It is primarily indicated for the prevention and control of bleeding episodes in patients with Hemophilia B (Factor IX deficiency). In the clinical research context at The University of Texas Health Science Center at Houston, Bebulin is utilized as part of a damage control resuscitation strategy to manage dilutional coagulopathy and thrombocytopenia in neonates and infants undergoing open-heart surgery with cardiopulmonary bypass. By providing exogenous clotting factors, it helps restore the hemostatic balance that is often disrupted by hemodilution and the consumption of factors during surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bebulin.